IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors

NCT07441174 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

92

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor Cancer
PDAC

Interventions

DRUG: IN10018 in combination with RNK08954

Sponsor

InxMed (Shanghai) Co., Ltd.

Collaborators

[object Object]
[object Object]